At a glance
- Originator Pfizer
- Class Neuroprotectants
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 27 Apr 2001 Phase-I clinical trials for Stroke in United Kingdom (Unknown route)